Screener
Gyre Therapeutics, Inc. GYRE Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Gyre Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
FAQ
- What is Gyre Therapeutics, Inc.'s debt-to-equity?
- Gyre Therapeutics, Inc. (GYRE) reported debt-to-equity of 0× in Q2 2026.
- How has Gyre Therapeutics, Inc.'s debt-to-equity changed year-over-year?
- Gyre Therapeutics, Inc.'s debt-to-equity increased by 109.9% year-over-year, from 0× to 0×.
- What is the long-term trend for Gyre Therapeutics, Inc.'s debt-to-equity?
- Over 4 years (2020 to 2025), Gyre Therapeutics, Inc.'s debt-to-equity has grown at a -8.7% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Gyre Therapeutics, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude